Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) [rubitecan] Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients.
Latest Information Update: 29 Jan 2020
At a glance
- Drugs Rubitecan (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 01 Dec 2011 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified June 2007).
- 15 Sep 2005 New trial record.